公开(公告)号：US20230339960A1

公开(公告)日：2023-10-26

申请号：US18342977

申请日：2023-06-28

申请人： Pfizer Inc.

发明人： JOHN DAVID TRZUPEK ,  KATHERINE LIN LEE ,  MARK EDWARD BUNNAGE ,  SEUNGIL HAN ,  DAVID HEPWORTH ,  FRANK ELDRIDGE LOVERING ,  JOHN PAUL MATHIAS ,  NIKOLAOS PAPAIOANNOU ,  BETSY SUSAN PIERCE ,  JOSEPH WALTER STROHBACH ,  STEPHEN WAYNE WRIGHT ,  CHRISTOPH WOLFGANG ZAPF ,  LORI KRIM GAVRIN ,  ARTHUR LEE ,  DAVID RANDOLPH ANDERSON ,  KEVIN JOSEPH CURRAN ,  CHRISTOPH MARTIN DEHNHARDT ,  EDDINE SAIAH ,  JOEL ADAM GOLDBERG ,  XIAOLUN WANG ,  HORNG-CHIH HUANG ,  RICHARD VARGAS ,  MICHAEL DENNIS LOWE ,  AKSHAY PATNY

IPC分类号： C07D491/056 ,  C07F7/18 ,  A61K31/4015 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07C69/94 ,  C07D207/08 ,  C07D207/26 ,  C07D207/267 ,  C07D207/273 ,  C07D209/52 ,  C07D215/48 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D239/86 ,  C07D239/88 ,  C07D263/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D498/04 ,  A61K31/40

CPC分类号： C07D491/056 ,  C07F7/1804 ,  A61K31/4015 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07C69/94 ,  C07D207/08 ,  C07D207/26 ,  C07D207/267 ,  C07D207/273 ,  C07D209/52 ,  C07D215/48 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D239/86 ,  C07D239/88 ,  C07D263/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D498/04 ,  A61K31/40

摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,




as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

公开(公告)号：US20190092750A1

公开(公告)日：2019-03-28

申请号：US16206166

申请日：2018-11-30

申请人： PFIZER INC.

发明人： KATHERINE LIN LEE ,  CHRISTOPHE PHILIPPE ALLAIS ,  CHRISTOPH MARTIN DEHNHARDT ,  LORI KRIM GAVRIN ,  SEUNGIL HAN ,  DAVID HEPWORTH ,  ARTHUR LEE ,  FRANK ELDRIDGE LOVERING ,  JOHN PAUL MATHIAS ,  DAFYDD RHYS OWEN ,  NIKOLAOS PAPAIOANNOU ,  EDDINE SAIAH ,  JOSEPH WALTER STROHBACH ,  JOHN DAVID TRZUPEK ,  STEPHEN WAYNE WRIGHT ,  CHRISTOPH WOLFGANG ZAPF

IPC分类号： C07D401/12 ,  C07D413/04 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/4745 ,  A61K45/06 ,  C07D401/14 ,  C07D207/273 ,  C07D491/18 ,  C07D471/04 ,  C07D413/14 ,  A61K31/4015

摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula 1a, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20180244646A1

公开(公告)日：2018-08-30

申请号：US15754650

申请日：2016-08-16

申请人： PFIZER INC.

发明人： KATHERINE LIN LEE ,  CHRISTOPHE PHILIPPE ALLAIS ,  CHRISTOPH MARTIN DEHNHARDT ,  LORI KRIM GAVRIN ,  SEUNGIL HAN ,  DAVID HEPWORTH ,  ARTHUR LEE ,  FRANK ELDRIDGE LOVERING ,  JOHN PAUL MATHIAS ,  DAFYDD RHYS OWEN ,  NIKOLAOS PAPAIOANNOU ,  EDDINE SAIAH ,  JOSEPH WALTER STROHBACH ,  JOHN DAVID TRZUPEK ,  STEPHEN WAYNE WRIGHT ,  CHRISTOPH WOLFGANG ZAPF

IPC分类号： C07D401/12 ,  A61K31/4709 ,  C07D413/14 ,  A61K31/4725 ,  A61K45/06 ,  C07D401/14 ,  C07D413/04 ,  C07D207/273 ,  A61K31/4015 ,  C07D491/18 ,  A61K31/4745 ,  C07D471/04 ,  A61K31/4375

CPC分类号： C07D401/12 ,  A61K31/4015 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/4745 ,  A61K45/06 ,  C07D207/273 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04 ,  C07D491/18

摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.